Please assess the completion status of the following clinical trial:

Trial Title: A Trial Evaluating the Blood Glucose-lowering Effect of NN1250 in Subjects With Type 2 Diabetes

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE1
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Type 2 diabetes mellitus (as diagnosed clinically) for at least 12 months~* Body mass index (BMI) below or equal to 35.0 kg/m2~Exclusion Criteria:~* Subject who has donated any blood or plasma in the past month or more than 500 mL within 3 months prior to screening~* Smoker (defined as a subject who is smoking more than 5 cigarettes or the equivalent per day)~* Not able or willing to refrain from smoking and use of nicotine gum or transdermal nicotine patches during the inpatient period

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- IDeg 100U/mL 0.4U/kg (Type: EXPERIMENTAL): None
- IDeg 100U/mL 0.6U/kg (Type: EXPERIMENTAL): None
- IDeg 100U/mL 0.8U/kg (Type: EXPERIMENTAL): None
- IDeg 200U/mL 0.6U/kg (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).